Shots:
- GeneScience has entered into an exclusive global ex-China license agreement with Yarrow, backed by RTW Investments, for GS-098 (YB-101 outside of China) to treat Graves’ disease (GD) & thyroid eye disease (TED)
- As per the deal, Yarrow will obtain exclusive global ex-China rights to develop, manufacture, & commercialize GS-098 for GD & TED, with GenSci retaining rights to develop & commercialize it in China
- In return, GeneSci will receive $70M upfront, $50M near-term development milestone, & further development, regulatory & commercial milestone payments, representing the total deal value of ~$1.365B, with tiered double-digit royalties on future net sales in licensed territories
Ref: Business Wire | Image: GeneScience & Yarrow | Press Release
Related News: Harbour BioMed and BMS Collaborate in ~$1.1B Deal to Advance Next-Generation Multi-Specific Antibodies
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
